Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential
Archiv der Pharmazie · 2026-07 · 359 (7)
DOI: 10.1002/ardp.70307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 12.07.2026. Verfasst von Yanjing Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China. Hauptthemen laut MEDLINE: Indoles, Antineoplastic Agents, Leukemia. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Doctoral research project of Hubei University of Science and Technology.
Abstract (Originalsprache)
Leukemia represents a heterogeneous and refractory hematological malignancy, with current clinical therapies, including conventional chemotherapy, targeted therapy, and hematopoietic stem cell transplantation, still limited by drug resistance, off‐target toxicity, and poor efficacy against high‐risk subtypes. Indole/azaindole is a privileged heterocyclic scaffold in medicinal chemistry with versatile structural modification potential and inherent antileukemic bioactivity. Rational hybridization of indole/azaindole with diverse pharmacophores has become a core strategy for developing novel antileukemic agents, thereby enabling synergistic efficacy, reversal of drug resistance, and reduced toxicity. This review systematically summarizes the research progress of indole‐based hybrids and closely related indole bioisosteres (azaindole hybrids) with antileukemic activity from 2021 to the present. Distinct from previous descriptive reviews, we stratified all candidate compounds by evidence hierarchy: in vitro antiproliferative activity, molecular mechanistic validation, and in vivo preclinical efficacy. This work focuses on structure‐activity relationships (SARs), multi‐target mechanisms, and preclinical pharmacological characteristics of indole‐ and azaindole‐based antileukemic hybrids, aiming to provide targeted guidance for the rational design and clinical translation of novel indole‐ and azaindole‐based antileukemic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
- School of Public Health and Nursing, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
ORCID-Profile: Yanjing Cheng, Yafei Zhuang
Förderung
- Doctoral research project of Hubei University of Science and Technology
Zitieren
APA
Cheng, Y., Chen, L., Zhao, D., Yu, J., & Zhuang, Y. (2026). Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential. Archiv der Pharmazie, 359(7). https://doi.org/10.1002/ardp.70307
Vancouver
Cheng Y, Chen L, Zhao D, Yu J, Zhuang Y. Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential. Archiv der Pharmazie. 2026;359(7). doi:10.1002/ardp.70307
BibTeX
@article{Cheng2026,
author = {Cheng, Yanjing and Chen, Lianlian and Zhao, Danchen and Yu, Jun and Zhuang, Yafei},
title = {Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential},
journal = {Archiv der Pharmazie},
year = {2026},
volume = {359},
number = {7},
doi = {10.1002/ardp.70307}
}
EUVIMED